Short answer
Pediatrix Medical Group, Inc. (MD) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $493M (down 3.6% year over year) with net income of $72M.
Q3 2025 key financials · XBRL
- Revenue
- $493M
- −3.6% YoY · +5.1% QoQ
- Net income
- $72M
- +268.8% YoY · +82.6% QoQ
- Operating margin
- 13.8%
- EPS (diluted)
- $0.84
- +265.2% YoY · +82.6% QoQ
Source: XBRL data from the Pediatrix Medical Group, Inc. (MD) Q3 2025 10-Q on SEC EDGAR. USD.
Pediatrix Medical Group, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: Medicaid Reform via One Big Beautiful Bill Act on July 4, 2025, imposing work requirements and increased patient cost-sharing, uncertain reimbursement impact
- Most materially updated risk: Exit of office-based pediatric practices finalized by Dec 31, 2024, shifting focus to hospital-based and maternal-fetal medicine to reduce operational complexity and costs
- Regulatory risk: No Surprises Act enforcement risks including potential CMS investigations and federal/state penalties for surprise billing non-compliance affecting revenue recovery from out-of-network services
- Market risk: Patient service revenue declined 3.6% QoQ due to practice dispositions despite 8.0% same-unit revenue growth, signaling near-term pressure from portfolio changes
- Financial risk: Cash and equivalents increased to $340.1 million as of Sept 30, 2025, with working capital up by $119.2 million from Dec 31, 2024 driven by improved revenue and faster accounts receivable collections (DSO down to 43.1 days)
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pediatrix Medical Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.